Company intelligence / Profile preview

Remedium Bio

Needham, Massachusetts, United Statesremedium-bio.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Remedium Bio’s lead candidate RMD1202—a single-injection GLP‑1 RA gene therapy for type 2 diabetes and obesity—has demonstrated preclinical proof-of-concept. The company’s Prometheus™ platform enables durable protein expression with post-treatment dose adjustment. Additional programs include a disease-modifying treatment for osteoarthritis (RMD1101) and other regenerative therapeutics targeting major chronic conditions. No clinical trial results have been published yet; the company remains at the preclinical stage.

Therapeutic areas
EndocrinologyRheumatologyNeurology
Modalities
Gene therapy (adjustable-dose platform)Protein/peptide delivery via gene therapy (e.g., GLP‑1 RA)Antibody delivery via gene therapyGrowth factor restoration
Industry
Biotech
02

Drug pipeline

14 assets

RMD1101

Preclinical

13 more assets in the full pipeline.

03

Partnerships

Wharton Alumni Angels (investor partnership)Ulu Ventures investment partnership to accelerate development of lead asset RMD1202 to first-in-human studies.

Beyond the preview

Go deeper on Remedium Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remedium Bio.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call